Altadyne acquires Stem Cell Therapy

By Jennifer Chiou

New York, Sept. 16 - Altadyne Inc. has acquired Stem Cell Therapy International Corp., according to a news release.

Stem Cell chief executive officer and president Calvin Cao and chief financial officer Daniel Sullivan hold the same positions in the newly merged company and are also part of its board.

"Our new board of directors plans to change the corporate name of the merged company to Stem Cell Therapy International, Inc. and to seek a new symbol from the NASD," Cao said in the release.

For now, Stem Cell Therapy will trade under the symbol "ATYD.PK."

Based in Tampa, Fla., Stem Cell Therapy sells and distributes stem cell products used in the treatment of patients suffering from degenerative disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.